HISUN(600267.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
HISUN
600267.SH
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others.
2.788 T
600267.SHMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking18/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.03%B
    • Profit Margin6.81%B
    • Gross Margin50.87%B
  • Growth ScoreC
    • Revenue YoY0.61%C
    • Net Profit YoY28.40%B
    • Total Assets YoY-13.71%E
    • Net Assets YoY4.77%C
  • Cash ScoreB
    • Cash Flow Margin316.13%A
    • OCF YoY0.61%C
  • Operating ScoreB
    • Turnover0.69B
  • Debt ScoreB
    • Gearing Ratio33.43%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively

    Wallstreetcn·
    SH
    688166
    -2.38%
    SZ
    000919
    -1.33%
    SH
    600267
    +0.37%
    Wallstreetcn·
    SH
    688166
    -2.38%
    SZ
    000919
    -1.33%
    SH
    600267
    +0.37%

    HISUN's revenue in 2025 is expected to be 10.55 billion yuan

    Donews·
    SH
    600267
    +0.37%
    Donews·
    SH
    600267
    +0.37%

    Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection

    Tip Ranks·
    SH
    512290
    -0.11%
    SZ
    159506
    -0.75%
    SZ
    159570
    -0.93%
    Tip Ranks·
    SH
    512290
    -0.11%
    SZ
    159506
    -0.75%
    SZ
    159570
    -0.93%

    China's pet prescription food welcomes a breakthrough player

    Wallstreetcn·
    SH
    600267
    +0.37%
    Wallstreetcn·
    SH
    600267
    +0.37%

    HISUN: Has cumulatively spent CNY 56.9915 million to repurchase 0.51% of its shares

    Zhitong·
    SH
    600267
    +0.37%
    Zhitong·
    SH
    600267
    +0.37%
    © 2026 Longbridge｜Disclaimer